Vriend J, Glogowska A
Cancers (Basel). 2025; 17(4).
PMID: 40002179
PMC: 11852889.
DOI: 10.3390/cancers17040575.
Di Fiore A, Bellardinelli S, Pirone L, Russo R, Angrisani A, Terriaca G
Neoplasia. 2023; 43:100926.
PMID: 37597490
PMC: 10462845.
DOI: 10.1016/j.neo.2023.100926.
Egolf S, Zou J, Anderson A, Simpson C, Aubert Y, Prouty S
Sci Adv. 2021; 7(50):eabj9141.
PMID: 34890228
PMC: 8664260.
DOI: 10.1126/sciadv.abj9141.
Chen S, Deng X, Sheng H, Rong Y, Zheng Y, Zhang Y
Mol Ther Nucleic Acids. 2021; 26:417-431.
PMID: 34552822
PMC: 8426460.
DOI: 10.1016/j.omtn.2021.07.024.
Doheny D, Manore S, Wong G, Lo H
Cells. 2020; 9(9).
PMID: 32957513
PMC: 7565963.
DOI: 10.3390/cells9092114.
Role and inhibition of GLI1 protein in cancer.
Mastrangelo E, Milani M
Lung Cancer (Auckl). 2018; 9:35-43.
PMID: 29628779
PMC: 5877502.
DOI: 10.2147/LCTT.S124483.
The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy.
Armas-Lopez L, Zuniga J, Arrieta O, Avila-Moreno F
Oncotarget. 2017; 8(36):60684-60703.
PMID: 28948003
PMC: 5601171.
DOI: 10.18632/oncotarget.19527.
In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
Benvenuto M, Masuelli L, De Smaele E, Fantini M, Mattera R, Cucchi D
Oncotarget. 2016; 7(8):9250-70.
PMID: 26843616
PMC: 4891038.
DOI: 10.18632/oncotarget.7062.
Genes targeted by the Hedgehog-signaling pathway can be regulated by Estrogen related receptor β.
Lu Y, Li J, Cheng J, Lubahn D
BMC Mol Biol. 2015; 16:19.
PMID: 26597826
PMC: 4657266.
DOI: 10.1186/s12867-015-0047-3.
Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup.
Miele E, Mastronuzzi A, Po A, Carai A, Alfano V, Serra A
Biomark Res. 2015; 3:13.
PMID: 26064523
PMC: 4462002.
DOI: 10.1186/s40364-015-0038-z.
Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy.
Pandolfi S, Stecca B
Expert Rev Mol Med. 2015; 17:e5.
PMID: 25660620
PMC: 4836208.
DOI: 10.1017/erm.2015.3.
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.
Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D
ACS Med Chem Lett. 2014; 1(3):130-4.
PMID: 24900187
PMC: 4007689.
DOI: 10.1021/ml1000307.
Genome-wide consequences of deleting any single gene.
Teng X, Dayhoff-Brannigan M, Cheng W, Gilbert C, Sing C, Diny N
Mol Cell. 2013; 52(4):485-94.
PMID: 24211263
PMC: 3975072.
DOI: 10.1016/j.molcel.2013.09.026.
MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors.
Berenguer J, Herrera A, Vuolo L, Torroba B, Llorens F, Sumoy L
Mol Cell Biol. 2013; 33(14):2706-17.
PMID: 23671190
PMC: 3700129.
DOI: 10.1128/MCB.00338-13.
Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression.
Zheng J, Xiong D, Sun X, Wang J, Hao M, Ding T
Cancer Microenviron. 2012; 5(3):285-93.
PMID: 22528874
PMC: 3460058.
DOI: 10.1007/s12307-012-0103-1.
Targeting the Hedgehog pathway in cancer.
Gupta S, Takebe N, LoRusso P
Ther Adv Med Oncol. 2011; 2(4):237-50.
PMID: 21789137
PMC: 3126020.
DOI: 10.1177/1758834010366430.
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer.
Mendrysa S, Ghassemifar S, Malek R
Genes Cancer. 2011; 2(4):431-42.
PMID: 21779511
PMC: 3135640.
DOI: 10.1177/1947601911409736.
Development and cancer of the cerebellum.
Hatten M, Roussel M
Trends Neurosci. 2011; 34(3):134-42.
PMID: 21315459
PMC: 3051031.
DOI: 10.1016/j.tins.2011.01.002.
Cerebellum development and medulloblastoma.
Roussel M, Hatten M
Curr Top Dev Biol. 2011; 94:235-82.
PMID: 21295689
PMC: 3213765.
DOI: 10.1016/B978-0-12-380916-2.00008-5.
Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases.
Pizem J, Popovic M, Cor A
J Neurooncol. 2010; 103(3):459-67.
PMID: 20953661
DOI: 10.1007/s11060-010-0431-2.